Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis

Daisuke Takahari; Takuya Matsunaga; Akihito Fujimi; Tomoki Kikuchi; Ryoya Seki; Ikuta Tanaka; Naofumi Takemoto; Takehide Akiyama; Tsutomu Sato; Takeshi Terui; Katsuhisa Kogawa; Junji Kato; Toshiro Kura; Takeshi Maeda; Yoshiro Niitsu

Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis

Daisuke Takahari^*, Takuya Matsunaga, Akihito Fujimi, Tomoki Kikuchi, Ryoya Seki, Ikuta Tanaka, Naofumi Takemoto, Takehide Akiyama, Tsutomu Sato, Takeshi Terui, Katsuhisa Kogawa, Junji Kato, Toshiro Kura, Takeshi Maeda, Yoshiro Niitsu

^*この論文の責任著者

血液内科

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

2 被引用数 (Scopus)

抄録

We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.

本文言語	英語
ページ（範囲）	924-930
ページ数	7
ジャーナル	[Rinshō ketsueki] The Japanese journal of clinical hematology
巻	43
号	10
出版ステータス	出版済み - 2002/10

ASJC Scopus 主題領域

医学一般

フィンガープリント

「Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Takahari, D., Matsunaga, T., Fujimi, A., Kikuchi, T., Seki, R., Tanaka, I., Takemoto, N., Akiyama, T., Sato, T., Terui, T., Kogawa, K., Kato, J., Kura, T., Maeda, T., & Niitsu, Y. (2002). Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis. [Rinshō ketsueki] The Japanese journal of clinical hematology, 43(10), 924-930.

@article{b0ad847c935c4a7faf6f47295e214e05,

title = "Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis",

abstract = "We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.",

author = "Daisuke Takahari and Takuya Matsunaga and Akihito Fujimi and Tomoki Kikuchi and Ryoya Seki and Ikuta Tanaka and Naofumi Takemoto and Takehide Akiyama and Tsutomu Sato and Takeshi Terui and Katsuhisa Kogawa and Junji Kato and Toshiro Kura and Takeshi Maeda and Yoshiro Niitsu",

year = "2002",

month = oct,

language = "英語",

volume = "43",

pages = "924--930",

journal = "[Rinshō ketsueki] The Japanese journal of clinical hematology",

issn = "0485-1439",

publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",

number = "10",

}

Takahari, D, Matsunaga, T, Fujimi, A, Kikuchi, T, Seki, R, Tanaka, I, Takemoto, N, Akiyama, T, Sato, T, Terui, T, Kogawa, K, Kato, J, Kura, T, Maeda, T & Niitsu, Y 2002, 'Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 43, no. 10, pp. 924-930.

Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis. / Takahari, Daisuke; Matsunaga, Takuya; Fujimi, Akihito その他.
In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 43, No. 10, 10.2002, p. 924-930.

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

TY - JOUR

T1 - Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis

AU - Takahari, Daisuke

AU - Matsunaga, Takuya

AU - Fujimi, Akihito

AU - Kikuchi, Tomoki

AU - Seki, Ryoya

AU - Tanaka, Ikuta

AU - Takemoto, Naofumi

AU - Akiyama, Takehide

AU - Sato, Tsutomu

AU - Terui, Takeshi

AU - Kogawa, Katsuhisa

AU - Kato, Junji

AU - Kura, Toshiro

AU - Maeda, Takeshi

AU - Niitsu, Yoshiro

PY - 2002/10

Y1 - 2002/10

N2 - We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.

AB - We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate. Hematological complete remission and significant regression of bone marrow fibrosis were observed in both patients. The large amount of TGF-beta produced by increased bone marrow megakaryocytes might have caused the myelofibrosis, and it was revealed that imatinib mesylate brought about regression of the myelofibrosis by reducing the number of megakaryocytes in both patients.

UR - http://www.scopus.com/inward/record.url?scp=0036778241&partnerID=8YFLogxK

M3 - 学術論文

C2 - 12462028

AN - SCOPUS:0036778241

SN - 0485-1439

VL - 43

SP - 924

EP - 930

JO - [Rinshō ketsueki] The Japanese journal of clinical hematology

JF - [Rinshō ketsueki] The Japanese journal of clinical hematology

IS - 10

ER -